Allergy Rhinol (Providence). 2017 Oct 01;8(3):126-131. doi: 10.2500/ar.2017.8.0207.
The study of a possible correlation between serum levels of interleukin 17 and clinical severity in patients with allergic rhinitis.
Allergy & rhinology (Providence, R.I.)
Mai Aly Gharib Aly, Mohamed Tawfik El Tabbakh, Waheed Fawzy Heissam, Said Hamed Abbadi, Shute
Affiliations
Affiliations
- From the Microbiology and Immunology Department, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.
- ENT Department, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.
PMID: 29070269
PMCID: PMC5662537 DOI: 10.2500/ar.2017.8.0207
Abstract
INTRODUCTION: Allergic rhinitis (AR) is one of the most common allergic diseases, which affects ∼20% of the world's population. T-helper (Th) type 2 cells produce interleukin (IL) 4 and IL-13, and mediate allergic responses, and these cytokines have been extensively studied as key players in the atopic airway diseases. However, the involvement of Th17 cells and IL-17 in AR has not been clearly examined.
AIM: To reevaluate AR clinical severity with serum IL-17, whether IL-17 affects the disease alone or in contribution with the atopic predisposition.
PATIENTS AND METHODS: During an 18-month period, 39 individuals were divided into three groups: A, (13 control), B (13 with mild-to-moderate AR), and C (13 with severe AR). Both group B and group C patients (26) were subjected to clinical examination and allergy skin testing, and to measurement of both total serum immunoglobulin E (IgE) and IL-17 levels. Eleven patients with AR then were exposed to 6 months of cluster immunotherapy, whereas the rest of the patients were not exposed.
RESULTS: Revealed a significant elevation of serum IL-17 levels with an associated increase in serum IgE in the patients with AR compared with controls and revealed that the serum levels of both total serum IgE and IL-17 decreased significantly after cluster immunotherapy.
CONCLUSION: These preliminary results added new data about the use of injective immunotherapy as well as reported on the use of sublingual immunotherapy.
References
- Am J Respir Crit Care Med. 2009 Oct 15;180(8):720-30 - PubMed
- J Allergy Clin Immunol. 2007 Apr;119(4):780-91 - PubMed
- Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2010 Jan;24(2):53-6 - PubMed
- Zhongguo Dang Dai Er Ke Za Zhi. 2014 Dec;16(12):1206-10 - PubMed
- Lung. 2012 Oct;190(5):487-95 - PubMed
- Allergol Int. 2008 Jun;57(2):121-34 - PubMed
- Respir Res. 2006 Nov 03;7:135 - PubMed
- Asia Pac Allergy. 2013 Jul;3(3):186-93 - PubMed
- J Allergy Clin Immunol. 2012 Nov;130(5):1049-62 - PubMed
- Otolaryngol Head Neck Surg. 2003 Sep;129(3):274-9 - PubMed
- Allergy. 2003 Sep;58(9):905-11 - PubMed
- Curr Opin Otolaryngol Head Neck Surg. 2012 Feb;20(1):1-8 - PubMed
- Allergy. 2010 Feb;65(2):208-12 - PubMed
- Thorax. 2000 Oct;55 Suppl 2:S22-3 - PubMed
- Allergy. 2011 Aug;66(8):989-98 - PubMed
- Lin Chuang Er Bi Yan Hou Ke Za Zhi. 2006 Jul;20(14):625-7 - PubMed
- Allergy Asthma Proc. 2016 Jan-Feb;37(1):35-42 - PubMed
- Ann Allergy Asthma Immunol. 2008 Mar;100(3 Suppl 3):S1-148 - PubMed
- J Allergy Clin Immunol. 2017 Oct;140(4):950-958 - PubMed
- Immunol Lett. 2013 Nov-Dec;156(1-2):140-8 - PubMed
- Immunol Allergy Clin North Am. 2011 Aug;31(3):433-9 - PubMed
- Pediatr Allergy Immunol. 2010 Feb;21(1 Pt 2):e174-84 - PubMed
- J Allergy Clin Immunol. 2008 Aug;122(2 Suppl):S1-84 - PubMed
- Cytokine. 2015 Sep;75(1):181-5 - PubMed
- Ann Allergy Asthma Immunol. 2008 Dec;101(6):580-92 - PubMed
- Toxicol Pathol. 2012;40(2):205-15 - PubMed
- J Invest Dermatol. 2010 Nov;130(11):2621-8 - PubMed
- J Allergy Clin Immunol. 2011 Jan;127(1 Suppl):S1-55 - PubMed
- N Engl J Med. 2015 Jan 29;372(5):456-63 - PubMed
Publication Types